AstraZeneca (AZNCF) News Today $140.26 -1.14 (-0.81%) As of 07/11/2025 01:35 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartDividendFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock AZNCF Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period AstraZeneca drug may lead to lower blood pressure, trial suggests3 hours ago | lse.co.ukAstraZeneca shares gain after drug shows success in late-stage hypertension trial3 hours ago | in.investing.comAstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancerJuly 4, 2025 | msn.comAstraZeneca boost as EU approves cancer drugJuly 4, 2025 | msn.comSummit Therapeutics stock rises after report of potential $15B AstraZeneca dealJuly 3, 2025 | finance.yahoo.comAstraZeneca exit is a frightening prospect for the City and the governmentJuly 2, 2025 | msn.comTreasury faces £1bn blow from AstraZeneca exit as pharma giant's boss mulls New York moveJuly 2, 2025 | msn.comAstraZeneca exit: here’s what it really means for the UKJuly 2, 2025 | msn.comLondon's IPO Crisis Worsens--and AstraZeneca Could Join the ExodusJuly 2, 2025 | finance.yahoo.comAstraZeneca Gains as U.S. Listing Move ConsideredJuly 2, 2025 | finance.yahoo.comAstraZeneca may quit London stock marketJuly 2, 2025 | finance.yahoo.comAstraZeneca CEO Wants to Move Listing to US, Times ReportsJuly 2, 2025 | bloomberg.comLondon’s New Listings Hit 28-Year Low as AstraZeneca Weighs ExitJuly 2, 2025 | bloomberg.comAstraZeneca defies Trump to bet on ChinaJune 28, 2025 | finance.yahoo.comOnco-Innovations Limited: Onco-Innovations Welcomes AstraZeneca's Interest in Founding Role in PROmAI - an Inka-led AI-Oncology ConsortiumJune 27, 2025 | finanznachrichten.deAstraZeneca sets up ₹166 cr Global Hub to boost AI driven healthcareJune 27, 2025 | msn.comAstraZeneca’s Anifrolumab PRIM Program: A New Study on Pregnancy OutcomesJune 26, 2025 | msn.comApproval for AstraZeneca’s Datroway drug a ’minor positive’ for shares: JPMorganJune 24, 2025 | investing.comAstraZeneca and Daiichi hail US approval of Datroway for lung cancerJune 24, 2025 | lse.co.ukAstraZeneca Inks China AI Research Deal For Chronic DiseasesJune 14, 2025 | msn.comAstraZeneca in deal with China firm worth up to £4bnJune 13, 2025 | msn.comAstraZeneca signs AI research deal with China's CSPC for chronic diseasesJune 13, 2025 | msn.comAstraZeneca signs $5.2bn deal to develop drugs for chronic disease with Chinese biotechJune 13, 2025 | ft.comAstraZeneca signs US$5 billion research deal with China’s CSPCJune 13, 2025 | msn.comKeeping AstraZeneca's Edge in Oncology: Vanguards of Health CareJune 12, 2025 | bloomberg.comFDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZenecaJune 10, 2025 | msn.comPharmaceutical company AstraZeneca sues Utah Attorney General over discount medication lawJune 7, 2025 | msn.comAstraZeneca sues Utah attorney general over new drug pricing lawJune 7, 2025 | msn.comASCO25: AstraZeneca’s novel trial design for camizestrant pays off in breast cancerJune 3, 2025 | finance.yahoo.comASCO 2025: AstraZeneca’s novel trial design for camizestrant pays off in breast cancerJune 2, 2025 | finance.yahoo.comAstraZeneca hails Imfinzi results on early stage gastric cancerJune 2, 2025 | lse.co.ukAstraZeneca Pharma Shares Jump, Strong Q4 Results Boost StockJune 2, 2025 | msn.comAstraZeneca unveils drug to treat mutating breast cancer before it starts to growJune 1, 2025 | ft.comAstraZeneca Breast Cancer Pill Slows Disease by Over Six MonthsJune 1, 2025 | msn.comAstraZeneca agrees to $51 million settlement in Seroquel antitrust class actionMay 30, 2025 | reuters.comDanaher, AstraZeneca Form Partnership For Diagnostic DevelopmentMay 29, 2025 | marketwatch.comAstraZeneca bladder cancer drug Imfinzi recommended for EU approvalMay 27, 2025 | lse.co.ukAstraZeneca (LSE:AZN) Gains EU Recommendation For Imfinzi in Bladder Cancer TreatmentMay 27, 2025 | finance.yahoo.comAptar Digital to use AstraZeneca’s AI algorithms for CKD detectionMay 23, 2025 | finance.yahoo.comAptar Digital Health Announces Licensing Agreement With AstraZeneca to Develop AI-Powered Screening AlgorithmsMay 22, 2025 | finance.yahoo.comAirsupra shows significant improvement in asthma treatment, AstraZeneca revealsMay 20, 2025 | au.investing.comAstraZeneca says Airsupra reduced severe asthma risk by 47%May 20, 2025 | finance.yahoo.comAstraZeneca (LSE:AZN) Reports Positive AIRSUPRA Results Reducing Severe Asthma RisksMay 20, 2025 | finance.yahoo.comAstraZeneca PLC: Acquisition of EsoBiotec completedMay 20, 2025 | finanznachrichten.deAstraZeneca completes EsoBiotec acquisition for up to USD1 billionMay 20, 2025 | lse.co.ukAstraZeneca means 'a road to death' in Latin?May 20, 2025 | msn.comAbu Dhabi, AstraZeneca forge strategic partnership to enhance COPD awareness, care in emirateMay 14, 2025 | msn.comAstraZeneca’s growth prospects are as attractive as ever. Keep buyingMay 14, 2025 | finance.yahoo.com21 analysts advised buy AstraZeneca shares in January – see what £10k invested then is worth nowMay 13, 2025 | msn.comAstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder CancerMay 10, 2025 | uk.finance.yahoo.com Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZNCF and its competitors with MarketBeat's FREE daily newsletter. Email Address AZNCF Media Mentions By Week AZNCF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZNCF News Sentiment▼0.511.01▲Average Medical News Sentiment AZNCF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZNCF Articles This Week▼25▲AZNCF Articles Average Week Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZNCF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 4Front Ventures News Today Ainos News Today Algernon Pharmaceuticals News Today Allstar Health Brands News Today Arno Therapeutics News Today AVAX Technologies News Today BriaCell Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:AZNCF) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
